Inactive Instrument
Eiger BioPharmaceuticals Share Price
Stocks
EIGR
US28249U2042
Biotechnology & Medical Research
OTC Markets Traded| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Tech/Sci/R&D Officer | 59 | 17/04/2022 | |
Douglas Staut
PRN | Corporate Officer/Principal | - | 18/04/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 31/10/23 | Propel Bio Management LLC
| Buy | Company | 278,239 | 0.6281% | |
| 31/10/23 | Propel Bio Management LLC
| Buy | Company | 24,332 | 0.0549% | |
| 18/10/23 | Propel Bio Management LLC
| Other | Company | 5,096,986 | 11.5065% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | +6.25% | - | - | 12.59M | ||
| -1.29% | -1.76% | +51.98% | +64.66% | 66.33B | ||
| -0.09% | +2.79% | +10.75% | +95.02% | 60.62B | ||
| +0.63% | +1.64% | +24.25% | +89.70% | 55.5B | ||
| -0.92% | -1.10% | +9.59% | +118.20% | 47.58B | ||
| -0.03% | -4.99% | +22.58% | +29.37% | 43.69B | ||
| -3.19% | -16.50% | +141.73% | +686.49% | 37.27B | ||
| +0.23% | +1.66% | +14.85% | +49.06% | 36.57B | ||
| +2.35% | -3.61% | +78.64% | +60.70% | 32.22B | ||
| +1.60% | +5.97% | -37.67% | +403.40% | 26.58B | ||
| Average | -0.06% | +0.33% | +35.19% | +177.40% | 45B | |
| Weighted average by Cap. | -0.21% | +0.33% | +35.06% | +152.55% |
Employees
25
















